CA2106172A1 - Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention - Google Patents

Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention

Info

Publication number
CA2106172A1
CA2106172A1 CA2106172A CA2106172A CA2106172A1 CA 2106172 A1 CA2106172 A1 CA 2106172A1 CA 2106172 A CA2106172 A CA 2106172A CA 2106172 A CA2106172 A CA 2106172A CA 2106172 A1 CA2106172 A1 CA 2106172A1
Authority
CA
Canada
Prior art keywords
aminobenzoic acid
treatment
coronary intervention
dimethoxycinnamoyl
restenosis associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2106172A
Other languages
French (fr)
Other versions
CA2106172C (en
Inventor
Hideo Tamai
Kinzo Ueda
Yung-Sheng Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Hideo Tamai
Kinzo Ueda
Yung-Sheng Hsu
Kissei Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hideo Tamai, Kinzo Ueda, Yung-Sheng Hsu, Kissei Pharmaceutical Co., Ltd. filed Critical Hideo Tamai
Publication of CA2106172A1 publication Critical patent/CA2106172A1/en
Application granted granted Critical
Publication of CA2106172C publication Critical patent/CA2106172C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

This invention provides a pharmaceutical composition for the treatment or prevention of restenosis associated with coronary intervention, containing, as an active ingredient, 2-(3,4-dimethyoxycinnamoyl)aminobenzoic acid or a pharmaceutically acceptable salt thereof and the use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical for the treatment or prevention of restenosis associated with coronary intervention. A 600 mg dosage of 2-(3,4-dimethoxy-cinnamoyl)aminobenzoic acid for a treatment period of three consecutive months after coronary intervention lowers the incidence of restenosis, and reduces the degree of stenosis in patients.
CA002106172A 1992-09-14 1993-09-14 Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the treatment of restenosis associated with coronary intervention Expired - Fee Related CA2106172C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4288086A JP2617407B2 (en) 1992-09-14 1992-09-14 Preventive and therapeutic agent for intimal cell hyperproliferative disease
JP288086/92 1992-09-14

Publications (2)

Publication Number Publication Date
CA2106172A1 true CA2106172A1 (en) 1994-03-15
CA2106172C CA2106172C (en) 2001-01-02

Family

ID=17725612

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002106172A Expired - Fee Related CA2106172C (en) 1992-09-14 1993-09-14 Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the treatment of restenosis associated with coronary intervention

Country Status (7)

Country Link
US (1) US5385935A (en)
EP (1) EP0588518B1 (en)
JP (1) JP2617407B2 (en)
KR (1) KR100252410B1 (en)
CA (1) CA2106172C (en)
DE (1) DE69310065T2 (en)
HK (1) HK1005425A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1996040098A2 (en) 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
NZ331339A (en) * 1996-02-15 2001-02-23 Kissei Pharmaceutical Neovascularization inhibitor comprising N-(3, 4-dimethoxycinnamoyl)anthranilic acid
JPH09278653A (en) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd Retinal disease-treating preparation
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention
CA2278421A1 (en) * 1997-02-14 1998-08-20 Kissei Pharmaceutical Co., Ltd. Drugs inhibiting progress of pterygium and postoperative recurrence of the same
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6303655B1 (en) * 1997-04-18 2001-10-16 Kissei Pharmaceutical Co., Ltd. Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells
WO1999056663A2 (en) * 1998-05-05 1999-11-11 Scimed Life Systems, Inc. Stent with smooth ends
PL349926A1 (en) * 1999-02-03 2002-10-21 Smithkline Beecham Corp Method for the prevention or reduction of cardiovascular events associated with coronary intervention
WO2000045811A1 (en) * 1999-02-03 2000-08-10 Smithkline Beecham Corporation Method for the prevention or reduction of cariovascular events associated with coronary intervention
WO2001005394A1 (en) * 1999-07-16 2001-01-25 Kissei Pharmaceutical Co., Ltd. Agents inhibiting chronic rejection reactions after organ transplantation
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
WO2001062241A1 (en) * 2000-02-23 2001-08-30 Smithkline Beecham Corporation Method for the prevention or reduction of vascular access dysfunction
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
EP1516597A4 (en) * 2002-06-27 2010-11-10 Microport Medical Shanghai Co Drug eluting stent
US20080306126A1 (en) * 2004-01-05 2008-12-11 Fonseca Vivian A Peroxisome proliferator activated receptor treatment of hyperhomocysteinemia and its complications
US7473738B2 (en) * 2004-09-30 2009-01-06 Johnson & Johnson Vision Care, Inc. Lactam polymer derivatives
US8668703B2 (en) * 2006-12-01 2014-03-11 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
AU2010260885B2 (en) 2009-06-17 2015-03-12 Keio University Prophylactic and/or therapeutic agent for dysmenorrhea

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5640710B2 (en) * 1973-01-18 1981-09-22
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
US4337270A (en) * 1980-05-21 1982-06-29 Hisamitsu Pharmaceutical Co., Inc. Novel anthranilic acid derivatives

Also Published As

Publication number Publication date
DE69310065D1 (en) 1997-05-28
KR940006578A (en) 1994-04-25
HK1005425A1 (en) 1999-01-08
JP2617407B2 (en) 1997-06-04
JPH06135829A (en) 1994-05-17
EP0588518A1 (en) 1994-03-23
CA2106172C (en) 2001-01-02
EP0588518B1 (en) 1997-04-23
US5385935A (en) 1995-01-31
DE69310065T2 (en) 1997-11-20
KR100252410B1 (en) 2000-05-01

Similar Documents

Publication Publication Date Title
CA2106172A1 (en) Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention
CA2105180A1 (en) Compositions containing sumatriptan
CA2186039A1 (en) New oral pharmaceutical dosage form
EP0513702A3 (en) Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
CA2065809A1 (en) Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids
CA2125662A1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
CA2213700A1 (en) Pharmaceutical composition for piperidinoalkanol compounds
RO116342B1 (en) Oral liquid pharmaceutical composition
EP0375628A3 (en) Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
EP0620004A4 (en) Medicinal composition.
NO924066L (en) THERAPEUTIC AGENT
JP2005511619A5 (en)
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
CA2180178A1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
CA2120001A1 (en) Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
AR009446A1 (en) USE OF 2- (3,4-DIMETOXINAMOIL) AMINOBENZOIC ACID (TRANILAST) IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF LARESTENOSIS, PHARMACEUTICAL COMPOSITION AND PREPARATION PROCEDURE.
EP0523013A3 (en) Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases
CA2057456A1 (en) Anti depression pharmaceutical
ATE224716T1 (en) PHARMACEUTICAL COMPOSITIONS OF CINCHONINE DIHYDROCHLORIDE
HUP0200148A2 (en) Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention
IT1271354B (en) Preparation of a pharmaceutical form capable of combating hyperinsulinism
HUP0200129A2 (en) Use of n-(3'4'-dimethoxycinnamoyl) anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed